batten disease

StemCells Paring Losses After Drug Program End Triggers Opening Bell Skid

Published on Fri, 04/08/2011 - 11:28
By FNNO Staff in General Interest, stem, batten disease, clinical trial, health, medical, patient, stem cells, stemcells, treatment, News Update

The company said it could not find enough test patients in its Phase Ib clinical trial for the last six months. The disease afflicts mainly children.

batten disease, clinical trial, health, medical, patient, stem cells, stemcells, treatment

StemCells Inc. (STEM) is down just over 9% but it is paring losses from its opening bell skid to 73 cents, sparked by the company's announcement that it is ending its program for a stem-cell treatment for Batten disease.

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

XL Capital Looks to Continue to Trade Ab...

Shares of XL Capital (NYSE:XL) traded today at $35.52, breaking its 52-week high. So f ...

Skechers U.S.A. Makes a Move: Up 1.3%...

Skechers U.S.A. (NYSE:SKX) is one of today's biggest movers, up 1.3% to $54.10. The Do ...

Deckers Outdoor Shares Sinking Lower, Do...

Deckers Outdoor (NASDAQ:DECK) is one of today's biggest movers, down 1.3% to $89.57. T ...

Verizon Communications: The Winning Stre...

Verizon Communications (NYSE:VZ) traded at a new 52-week high today of $53.66. So far ...

Stock Investors Sell Off Shares of Shutt...

Shutterfly (NASDAQ:SFLY), a company whose shares are moving quickly, is trading 1.3% lo ...

Watch for Continued Gains in Shares of U...

Shares of Universal Health Services (NYSE:UHS) traded today at $110.43, breaking its 52 ...

Stock Investors Sell Off Shares of Lulul...

Lululemon Athletica (NASDAQ:LULU) is a company whose shares are active, trading 1.3% lo ...

Shares of UDR Have Risen Above Previous ...

Shares of UDR (NYSE:UDR) traded at a new 52-week high today of $29.36. This new high w ...

Most Popular Video News